AimedBio and Boehringer Ingelheim Begin Phase I Study of BI 4060107
The first patient has been dosed in the Phase I study of BI 4060107, an investigational antibody-drug conjugate discovered by AimedBio and developed by Boehringer Ingelheim under a global collaboration and licensing agreement.